Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study - Celldex Therapeutics

Celldex has discontinued its Phase 2 trial of barzolvolimab for prurigo nodularis after failing to meet primary and secondary endpoints.

Raccontata dabenzinga.com